This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Most of the epidemiological data were derived from primary studies that were not described. Survival with BE and HGD and early oesophageal adenocarcinoma came from the National Cancer Institute Surveillance Epidemiology and End Results (SEER) database. Some mortality data followed the age-specific mortality of the Canadian male population (life tables).
Methods used to judge relevance and validity, and for extracting data
Clinical inputs with the three main strategies were obtained from a review of the literature review, but details were given only for PDT. Published reviews and proceedings from key conferences were also searched. No information on the primary studies was provided.
Measure of benefits used in the economic analysis
The summary benefit measures were life-years (LYs) in the cost-effectiveness analysis and quality-adjusted life-years (QALYs) in the cost-utility analysis. Utility weights used to calculate the QALYs were defined only for the post-ESO state. This value was derived from a published study, but no details of the instruments used or the patient population were provided. Both benefit measures were discounted at an annual rate of 3%.
Direct costs
The analysis of the costs was carried out from the perspective of a third-party payer. It included the costs associated with PDT sessions, endoscopy with biopsy, and ESO. Physician services and hospital admissions and procedures were considered. The unit costs and the resource quantities were not presented separately. Canadian sources were used to derive costs whenever possible, otherwise US sources were used. For example, the costs of physician services were obtained from the Ontario Ministry of Health and Long-Term Care Schedule of Benefits. Hospital costs came from the Ontario Case Costing Initiative programme. Some market prices were communicated directly from the manufacturers. The resource use data were based mainly on expert opinion and consensus. Discounting was relevant, given that 5-year costs were evaluated, and an annual rate of 3% was used. The price year was 2003.
